PET Radiopharmaceuticals for Imaging Chemotherapy-Induced Cardiotoxicity

Overview

Journal Curr Cardiol Rep

Publisher Current Science

Specialty Cardiology & Vascular Diseases

Date 2020 Jun 21

PMID 32562004

Citations 8

Authors

Jothilingam Sivapackiam

Monica Sharma

Thomas H Schindler

Vijay Sharma

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Currently, cardiotoxicity is monitored through echocardiography or multigated acquisition scanning and is defined as 10% or higher LVEF reduction. The latter stage may represent irreversible myocardium injury and limits modification of therapeutic paradigms at earliest stages. To stratify patients for anthracycline-related heart failure, highly sensitive and molecularly specific probes capable of interrogating cardiac damage at the subcellular levels have been sought.

Recent Findings: PET tracers may provide noninvasive assessment of earliest changes within myocardium. These tracers are at nascent stages of development and belong primarily to (a) mitochondrial potential-targeted and (b) general ROS (reactive oxygen species)-targeted radiotracers. Given that electrochemical gradient changes at the mitochondrial membrane represent an upstream, and earliest event before triggering the production of the ROS and caspase activity in a biochemical cascade, the former category might offer interrogation of cardiotoxicity at earliest stages exemplified by PET imaging, using F-Mitophos and Ga-Galmydar in rodent models. Both categories of radiotracers may provide tools for monitoring chemotherapy-induced cardiotoxicity and interrogating therapeutic efficacy of cardio-protectants.

Citing Articles

Innovations in Nuclear Medicine Imaging for Reactive Oxygen Species: Applications and Radiopharmaceuticals.

Park J, Park S, Lee T, Lee S, Kim J, Oh S Antioxidants (Basel). 2024; 13(10).

PMID: 39456507 PMC: 11504556. DOI: 10.3390/antiox13101254.

Cancer therapy-related cardiac dysfunction and the role of cardiovascular imaging: systemic review and opinion paper from the Working Group on Cardio-Oncology of the Korean Society of Cardiology.

Cho I, You S, Cha M, Hwang H, Cho E, Kim H J Cardiovasc Imaging. 2024; 32(1):13.

PMID: 39075626 PMC: 11288116. DOI: 10.1186/s44348-024-00014-5.

Cardiac PET Imaging of ATP Binding Cassette (ABC) Transporters: Opportunities and Challenges.

Liu W, Mossel P, Schwach V, Slart R, Luurtsema G Pharmaceuticals (Basel). 2023; 16(12).

PMID: 38139840 PMC: 10748140. DOI: 10.3390/ph16121715.

Assessing Drug-Induced Mitochondrial Toxicity in Cardiomyocytes: Implications for Preclinical Cardiac Safety Evaluation.

Tang X, Wang Z, Hu S, Zhou B Pharmaceutics. 2022; 14(7).

PMID: 35890211 PMC: 9319223. DOI: 10.3390/pharmaceutics14071313.

PET imaging of mitochondrial function in acute doxorubicin-induced cardiotoxicity: a proof-of-principle study.

Detmer F, Alpert N, Moon S, Dhaynaut M, Guerrero J, Guehl N Sci Rep. 2022; 12(1):6122.

PMID: 35414642 PMC: 9005533. DOI: 10.1038/s41598-022-10004-6.

References

Sharma V . Radiopharmaceuticals for assessment of multidrug resistance P-glycoprotein-mediated drug transport activity. Bioconjug Chem. 2004; 15(6):1464-74. DOI: 10.1021/bc0498469. View

Chu W, Chepetan A, Zhou D, Shoghi K, Xu J, Dugan L . Development of a PET radiotracer for non-invasive imaging of the reactive oxygen species, superoxide, in vivo. Org Biomol Chem. 2014; 12(25):4421-31. PMC: 4122299. DOI: 10.1039/c3ob42379d. View

Sharma V, Beatty A, Wey S, Dahlheimer J, Pica C, Crankshaw C . Novel gallium(III) complexes transported by MDR1 P-glycoprotein: potential PET imaging agents for probing P-glycoprotein-mediated transport activity in vivo. Chem Biol. 2000; 7(5):335-43. DOI: 10.1016/s1074-5521(00)00111-3. View

Doyle L, Ross D . Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene. 2003; 22(47):7340-58. DOI: 10.1038/sj.onc.1206938. View

Cottet-Rousselle C, Ronot X, Leverve X, Mayol J . Cytometric assessment of mitochondria using fluorescent probes. Cytometry A. 2011; 79(6):405-25. DOI: 10.1002/cyto.a.21061. View

Gu J, Hu W, Zhang D . Resveratrol, a polyphenol phytoalexin, protects against doxorubicin-induced cardiotoxicity. J Cell Mol Med. 2015; 19(10):2324-8. PMC: 4594674. DOI: 10.1111/jcmm.12633. View

Riddell E, Lenihan D . The role of cardiac biomarkers in cardio-oncology. Curr Probl Cancer. 2018; 42(4):375-385. DOI: 10.1016/j.currproblcancer.2018.06.012. View

Sivapackiam J, Harpstrite S, Prior J, Mattingly S, Sharma V . (67/68)Galmydar: A metalloprobe for monitoring breast cancer resistance protein (BCRP)-mediated functional transport activity. Nucl Med Biol. 2016; 43(3):191-7. DOI: 10.1016/j.nucmedbio.2015.12.001. View

Sharma P, Allison J . The future of immune checkpoint therapy. Science. 2015; 348(6230):56-61. DOI: 10.1126/science.aaa8172. View

10.

Zhou S, Schuetz J, Bunting K, Colapietro A, Sampath J, Morris J . The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med. 2001; 7(9):1028-34. DOI: 10.1038/nm0901-1028. View

11.

Vilas G, Corvi M, Plummer G, Seime A, Lambkin G, Berthiaume L . Posttranslational myristoylation of caspase-activated p21-activated protein kinase 2 (PAK2) potentiates late apoptotic events. Proc Natl Acad Sci U S A. 2006; 103(17):6542-7. PMC: 1458920. DOI: 10.1073/pnas.0600824103. View

12.

Lewis W . Cardiomyopathy, nucleoside reverse transcriptase inhibitors and mitochondria are linked through AIDS and its therapy. Mitochondrion. 2005; 4(2-3):141-52. DOI: 10.1016/j.mito.2004.05.010. View

13.

Fani M, Andre J, Maecke H . 68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals. Contrast Media Mol Imaging. 2008; 3(2):67-77. DOI: 10.1002/cmmi.232. View

14.

Davis S, Weiss M, Wong J, Lampidis T, Chen L . Mitochondrial and plasma membrane potentials cause unusual accumulation and retention of rhodamine 123 by human breast adenocarcinoma-derived MCF-7 cells. J Biol Chem. 1985; 260(25):13844-50. View

15.

Hurst J . Cancer immunotherapy innovator James Allison receives the 2015 Lasker~DeBakey Clinical Medical Research Award. J Clin Invest. 2015; 125(10):3732-6. PMC: 4607124. DOI: 10.1172/JCI84236. View

16.

Aggarwal S, Kamboj J, Arora R . Chemotherapy-related cardiotoxicity. Ther Adv Cardiovasc Dis. 2013; 7(2):87-98. DOI: 10.1177/1753944712474332. View

17.

Sivapackiam J, Kabra S, Speidel S, Sharma M, Laforest R, Salter A . 68Ga-Galmydar: A PET imaging tracer for noninvasive detection of Doxorubicin-induced cardiotoxicity. PLoS One. 2019; 14(5):e0215579. PMC: 6532866. DOI: 10.1371/journal.pone.0215579. View

18.

Zhang W, Cai Z, Li L, Ropchan J, Lim K, Boutagy N . Optimized and Automated Radiosynthesis of [F]DHMT for Translational Imaging of Reactive Oxygen Species with Positron Emission Tomography. Molecules. 2016; 21(12). PMC: 5505691. DOI: 10.3390/molecules21121696. View

19.

Hendrikse N, De Vries E, van der Graaf W, Hospers G, Willemsen A, Vaalburg W . A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res. 1999; 59(10):2411-6. View

20.

Blanco J, Sun C, Landier W, Chen L, Esparza-Duran D, Leisenring W . Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group. J Clin Oncol. 2011; 30(13):1415-21. PMC: 3383117. DOI: 10.1200/JCO.2011.34.8987. View